Gujarat Themis Biosyn Limited Signs Agreement to Acquire Sanofi's Anti-Infective Brand Portfolio
Gujarat Themis Biosyn Limited announced an Asset Purchase Agreement with Sanofi, the French holding company of the Sanofi group headquartered in Paris. The agreement enables Gujarat Themis Biosyn Limited to acquire a significant portfolio of anti-tuberculosis (TB) and anti-infective branded generic products, along with associated trademark rights.The acquisition targets 13 established branded generic products that possess a strong presence across more than 55 countries in Europe, the Middle East, and Africa. This portfolio generated net sales of approximately EURO 62 million for the year ended 2025.
The transaction represents a strategic effort by Gujarat Themis Biosyn Limited to bolster its global generic pharmaceuticals platform and enhance its presence within the anti-infective segment. Acquiring this portfolio will provide immediate access to regulated and semi-regulated markets, thereby expanding the company's international footprint. Furthermore, the transaction is anticipated to facilitate forward integration, allowing GTBL to leverage its existing capabilities in fermentation-based intermediates and APIs to support the acquired finished dosage formulations portfolio and improve realization across the value chain.
The asset purchase details are as follows:
| Detail | Description |
|---|---|
| Acquirer | Gujarat Themis Biosyn Limited |
| Seller | Sanofi, French holding Company of the Sanofi group |
| Acquired Products | 13 established branded generic products |
| Geographic Reach | Over 55 countries (Europe, Middle East, and Africa) |
| Nature of Transaction | Asset Purchase (no acquisition of legal entity, manufacturing facilities, or employees) |
| Total Consideration | Euro 158 Million |
The cost of the acquisition is set at Euro 158 Million, payable in cash at the closing date.
The revenue generated by the 13 established branded generic products from the last three financial years was:
| Financial Year | Revenue |
|---|---|
| FY23 | Euro 66 million |
| FY24 | Euro 67 million |
| FY25 | Euro 62 million |
The transaction is expected to close by the end of December 2026. The acquisition is not classified as a related party transaction.
GUJTHEM Stock Price Movement
On Thursday, Gujarat Themis Biosyn Limited shares slipped by 1.50%, settling at ₹324.42. The equity posted a volume of 29,125 shares traded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.